Search results for Abb Genix Ai

Novo teams with OpenAI; Ideaya gets muted response to eye drug data

Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into radiopharmaceuticals and a GSK cancer drug showed early prom...

ApexGO: AI-Driven Approach to Faster Antibiotic Discovery

Researchers at the University of Pennsylvania developed ApexGO, an AI-powered system that optimizes antimicrobial peptides, rapidly improving antibiotic candidates and identifying...

AWS Launches Amazon Bio Discovery Agentic AI to Accelerate Drug Development

AWS's new AI platform grants researchers direct access to a broad library of biological foundation models for lab-in-the-loop drug discovery and brings enterprise-grade scale, priv...

Forecasting Protein Aggregation with an Improved Algorithm

An algorithm for assessing protein aggregation and designing more soluble proteins could help overcome a bottleneck in biologics production. The new, improved software helps manufa...

Multi-agent AI delivers reliable and scalable insights for single-cell omics

Today, we're exploring the transformative potential of AI in biopharma with our guest, Parashar Dhapola, co-founder and CEO of Nygen Analytics. The post Multi-agent AI delivers rel...

Bristol Myers deepens AI investment with Anthropic deal

The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-da...

Adaptive, Agent-Oriented Control for Biomanufacturing Systems

Agentic AI goes beyond predictive and generative AI and has the potential to enhance efficiency by integrating with existing manufacturing infrastructure, however, industrial bioma...

Skape Bio Unlocks Generalizable GPCR Drugs Using AI Protein Design

David Baker’s latest company is making medicines for a huge protein family once deemed undruggable. A new study generated miniproteins that target GPCRs across a diversity of recep...

Indegene Stock: How Is This Company Building the AI Backbone for Global Pharma? 

Synopsis: Indegene Limited is revolutionising life sciences by integrating generative AI into its domain-led operating model. By achieving record FY26 revenues of Rs.3,510 crore an...

BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows

BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared intelligence platform”...

Incyte pays Genesis $80M to expand AI-fueled drug discovery pact

Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of targets, continuing the biotech’s rapid embrace of AI in drug disc...

Life Science Update | March 2026

Advances in AI and genomic analysis will allow medical providers to tailor treatment for individual patients at the genome level, but challenges exist for protecting AI-assisted in...

AI Designs Miniprotein Switches for GPCR Targeting

New AI‑designed miniproteins precisely modulate GPCR signaling and reveal a new "receptor diversion" microscopy-based screening system for targeting receptors long considered diffi...

Ambry Genetics

Ambry Genetics Anonymous (not verified) Mon, 04/27/2026 - 11:16 field_thread_url https://cafepharma.com/boards/threads/ambry-genetics.575501/...

Metaphore Biotechnologies, Developer of Functional Antibody AI Drug Discovery Platform, Receives Investment from TOHO Ho...

On the 6th, TOHO Ventures, operated by Global Brain, announced that it has executed an investment in Metaphore Biotechnologies, a company developing an AI platform to accelerate th...

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

May 28 2026 - AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer admin Thu, 05/28/2026 - 11:51 Steady progress across the board today, with new appro...

<![CDATA[Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals ]]>

Abbott forecasts 6.5%-7.5% 2026 comparable sales growth while integrating Exact Sciences with $0.20 EPS dilution

<![CDATA[Winning in AI Overviews: Protecting Brand Accuracy in AI-Generated Answers]]>

AimwellBio Launches the System That Catches What AI Gets Wrong: Before It Reaches Patients, Boards, or Your Portfolio

AI is making life-or-death decisions in healthcare, and nobody is checking if the answers are real. AimwellBio is the first platform that does. FHIN founding cohort now forming.

Abbott lowers EPS guidance on Exact Sciences buy as shares slide

Abbott's first-quarter numbers reflect is operational complexity.

Biopharma Adopting AI Despite Remaining GMP Compliance Questions

AI is streamlining and accelerating process development and manufacturing, but more work is needed to understand how best to use the technology in compliance with the strict drug p...

Verge, following trial failure, rebrands its AI drug discovery ambitions

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to patients who best benefit from them.

Coalition of Biotechnology Companies Launch American Biotech Innovation Alliance

On May 5, 2025, a coalition of U.S. biotechnology companies announced the launch of the American Biotech Innovation Alliance (ABIA). ABIA states that it will “focus on a shared obj...